In a groundbreaking health shift, the price of CAR-T cancer treatment in the UAE is going to decline by a record 90%—from more than $1 million to a mere $100,000. It is part of a breakthrough agreement with international pharmaceutical partners. The historic turnaround brings one of the globe’s most costly treatments for cancer that much closer in the region.
CAR-T (Chimeric Antigen Receptor T-cell) therapy, characterized by its lofty success rates when treating some forms of blood cancers, was before out of patients’ reach on account of the treatment’s extremely high cost. The new drug pricing agreement brings life-saving promise within closer distance for thousands of them.
UAE health authorities stress that the agreement is just one facet of a wider plan to make advanced treatments more accessible while continuing to deliver world-class care. The nation is becoming a regional hub for advanced cancer therapies.
Experts believe this initiative will not only mitigate the financial stress on patients and their families but also promote earlier intervention and improved survival rates, a new era for cancer treatment throughout the Middle East.
